Revvity Key Executives
This section highlights Revvity's key executives, including their titles and compensation details.
Find Contacts at Revvity
(Showing 0 of )
Revvity Earnings
This section highlights Revvity's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2025 | 2025-04-28 | $0.96 | $1.01 |
| Read Transcript | Q4 | 2024 | 2025-01-31 | $1.37 | $1.42 |
| Read Transcript | Q3 | 2024 | 2024-11-04 | $1.13 | $1.28 |
| Read Transcript | Q2 | 2024 | 2024-07-29 | $1.12 | $1.22 |
| Read Transcript | Q1 | 2024 | 2024-04-29 | $0.94 | $0.98 |
| Read Transcript | Q4 | 2023 | 2024-02-01 | $1.15 | $1.25 |
| Read Transcript | Q3 | 2023 | 2023-11-05 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-06 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-11 | $1.06 | $1.01 |
Financial Statements
Access annual & quarterly financial statements for Revvity, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 29, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.76B | $2.75B | $3.31B | $5.07B | $3.78B |
| Cost of Revenue | $1.22B | $1.21B | $1.32B | $2.22B | $1.67B |
| Gross Profit | $1.54B | $1.54B | $1.99B | $2.85B | $2.11B |
| Gross Profit Ratio | 55.81% | 55.98% | 60.08% | 56.27% | 55.78% |
| Research and Development Expenses | $196.84M | $216.58M | $221.62M | $274.97M | $205.39M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $994.07M | $1.02B | $1.03B | $1.23B | $917.89M |
| Other Expenses | $- | $- | $25.26M | $36.41M | $-23.52M |
| Operating Expenses | $1.19B | $1.24B | $1.25B | $1.50B | $1.12B |
| Cost and Expenses | $2.41B | $2.45B | $2.57B | $3.72B | $2.80B |
| Interest Income | $73.19M | $72.13M | $3.59M | $2.24M | $1.01M |
| Interest Expense | $96.28M | $98.81M | $103.95M | $102.13M | $49.71M |
| Depreciation and Amortization | $427.85M | $431.77M | $427.00M | $311.44M | $246.51M |
| EBITDA | $848.01M | $713.56M | $1.30B | $1.73B | $1.20B |
| EBITDA Ratio | 30.78% | 25.94% | 39.26% | 34.07% | 31.79% |
| Operating Income | $346.74M | $300.56M | $742.70M | $1.33B | $978.58M |
| Operating Income Ratio | 12.59% | 10.93% | 22.43% | 26.29% | 25.87% |
| Total Other Income Expenses Net | $-30.61M | $-117.59M | $-90.86M | $-54.88M | $39.09M |
| Income Before Tax | $316.13M | $182.98M | $651.84M | $1.28B | $906.36M |
| Income Before Tax Ratio | 11.47% | 6.65% | 19.68% | 25.26% | 23.96% |
| Income Tax Expense | $33.05M | $3.47M | $129.16M | $347.60M | $178.27M |
| Net Income | $270.38M | $693.09M | $569.18M | $943.16M | $727.89M |
| Net Income Ratio | 9.81% | 25.20% | 17.19% | 18.61% | 19.24% |
| EPS | $2.24 | $5.56 | $4.51 | $8.12 | $6.53 |
| EPS Diluted | $2.20 | $5.55 | $4.50 | $8.08 | $6.49 |
| Weighted Average Shares Outstanding | 117.56M | 124.70M | 126.16M | 116.17M | 111.51M |
| Weighted Average Shares Outstanding Diluted | 122.82M | 124.81M | 126.43M | 116.67M | 112.08M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 30, 2025 | December 29, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | April 02, 2023 | January 01, 2023 | October 02, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $664.76M | $729.37M | $684.05M | $691.68M | $649.92M | $695.90M | $670.74M | $709.07M | $674.87M | $741.21M | $711.80M | $1.23B | $1.26B | $1.36B | $1.17B | $1.23B | $1.31B | $1.35B | $964.02M | $811.72M |
| Cost of Revenue | $289.22M | $317.08M | $299.23M | $306.18M | $386.11M | $402.05M | $298.22M | $306.74M | $292.60M | $309.33M | $291.96M | $625.11M | $580.21M | $615.20M | $534.85M | $543.28M | $522.54M | $527.54M | $436.58M | $364.37M |
| Gross Profit | $375.55M | $412.29M | $384.82M | $385.51M | $263.81M | $293.85M | $372.52M | $402.33M | $382.27M | $431.88M | $419.84M | $604.46M | $679.23M | $749.12M | $631.84M | $685.19M | $785.15M | $827.07M | $527.45M | $447.34M |
| Gross Profit Ratio | 56.49% | 56.53% | 56.26% | 55.73% | 40.59% | 42.23% | 55.54% | 56.74% | 56.64% | 58.27% | 58.98% | 49.16% | 53.93% | 54.91% | 54.16% | 55.78% | 60.04% | 61.06% | 54.71% | 55.11% |
| Research and Development Expenses | $53.60M | $49.21M | $49.14M | $48.13M | $50.36M | $49.60M | $53.04M | $57.25M | $56.69M | $54.54M | $53.52M | $73.35M | $76.61M | $80.32M | $68.61M | $65.82M | $60.22M | $56.82M | $50.13M | $49.52M |
| General and Administrative Expenses | $- | $- | $239.48M | $253.56M | $262.49M | $- | $250.75M | $269.31M | $- | $- | $- | $260.62M | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $-17.70M | $-93.16M | $- | $-497.00K | $-2.29M | $- | $- | $- | $-14.87M | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $249.72M | $245.04M | $239.48M | $235.85M | $169.33M | $167.10M | $250.25M | $267.02M | $231.06M | $198.00M | $233.17M | $245.76M | $334.39M | $355.25M | $339.05M | $281.82M | $251.41M | $263.05M | $225.25M | $221.03M |
| Other Expenses | $- | $-712.00K | $- | $17.69M | $- | $- | $-3.00M | $-3.52M | $18.40M | $41.88M | $- | $-2.93M | $2.67M | $25.92M | $2.05M | $1.32M | $7.12M | $-25.11M | $-2.40M | $582.00K |
| Operating Expenses | $303.32M | $293.54M | $286.67M | $283.98M | $219.69M | $216.69M | $303.29M | $324.27M | $306.15M | $294.41M | $312.44M | $319.11M | $411.00M | $435.57M | $407.65M | $347.64M | $311.63M | $319.87M | $275.38M | $270.55M |
| Cost and Expenses | $592.53M | $610.62M | $585.90M | $590.16M | $605.80M | $618.74M | $601.51M | $631.01M | $598.75M | $603.75M | $604.40M | $944.21M | $991.21M | $1.05B | $942.50M | $890.92M | $834.17M | $847.41M | $711.96M | $634.92M |
| Interest Income | $-10.08M | $9.83M | $22.76M | $20.51M | $20.09M | $18.36M | $23.45M | $25.05M | $- | $- | $25.26M | $762.00K | $595.00K | $919.00K | $544.00K | $367.00K | $411.00K | $348.00K | $205.00K | $192.00K |
| Interest Expense | $22.96M | $22.78M | $24.38M | $24.72M | $24.40M | $24.58M | $25.49M | $26.01M | $- | $- | $25.93M | $27.13M | $28.39M | $27.72M | $43.53M | $16.75M | $14.13M | $12.40M | $12.06M | $11.59M |
| Depreciation and Amortization | $-3.12M | $105.03M | $107.67M | $107.24M | $107.80M | $105.57M | $108.26M | $108.93M | $109.01M | $104.23M | $104.74M | $119.41M | $120.05M | $125.07M | $87.11M | $75.64M | $70.19M | $63.99M | $62.47M | $59.29M |
| EBITDA | $72.23M | $223.07M | $232.41M | $218.62M | $180.89M | $191.97M | $201.06M | $216.95M | $204.72M | $279.48M | $239.19M | $371.00M | $366.04M | $464.47M | $292.31M | $377.78M | $560.35M | $561.30M | $308.29M | $236.97M |
| EBITDA Ratio | 10.87% | 30.58% | 33.98% | 31.61% | 27.83% | 27.59% | 29.98% | 30.60% | 30.34% | 37.71% | 33.60% | 30.17% | 29.06% | 34.04% | 25.05% | 30.75% | 42.85% | 41.44% | 31.98% | 29.19% |
| Operating Income | $72.23M | $118.75M | $98.15M | $101.52M | $44.12M | $77.16M | $69.23M | $78.06M | $76.12M | $137.47M | $134.45M | $285.36M | $254.84M | $310.14M | $221.97M | $332.49M | $467.78M | $510.25M | $248.01M | $175.64M |
| Operating Income Ratio | 10.87% | 16.28% | 14.35% | 14.68% | 6.79% | 11.09% | 10.32% | 11.01% | 11.28% | 18.55% | 18.89% | 23.21% | 20.23% | 22.73% | 19.03% | 27.07% | 35.77% | 37.67% | 25.73% | 21.64% |
| Total Other Income Expenses Net | $-19.85M | $-24.19M | $2.21M | $938.00K | $-9.57M | $-45.78M | $-18.62M | $-6.50M | $-46.68M | $978.00K | $-28.64M | $-8.02M | $-37.05M | $1.53M | $-33.89M | $-22.33M | $12.71M | $-37.16M | $-14.25M | $-10.81M |
| Income Before Tax | $52.38M | $94.56M | $100.36M | $86.66M | $34.55M | $31.38M | $50.60M | $71.55M | $29.44M | $138.45M | $82.14M | $224.47M | $217.60M | $311.68M | $161.67M | $326.06M | $480.48M | $473.09M | $233.76M | $164.83M |
| Income Before Tax Ratio | 7.88% | 12.96% | 14.67% | 12.53% | 5.32% | 4.51% | 7.54% | 10.09% | 4.36% | 18.68% | 11.54% | 18.26% | 17.28% | 22.84% | 13.86% | 26.54% | 36.74% | 34.92% | 24.25% | 20.31% |
| Income Tax Expense | $10.71M | $6.17M | $6.97M | $14.06M | $5.85M | $-32.19M | $18.13M | $12.93M | $4.59M | $40.95M | $12.63M | $45.22M | $40.60M | $132.49M | $33.88M | $80.09M | $101.14M | $92.66M | $57.02M | $27.61M |
| Net Income | $42.24M | $94.64M | $93.39M | $79.11M | $26.01M | $78.56M | $9.50M | $35.56M | $569.48M | $127.66M | $69.51M | $179.21M | $176.96M | $190.18M | $127.74M | $245.93M | $379.31M | $380.36M | $176.70M | $137.16M |
| Net Income Ratio | 6.35% | 12.98% | 13.65% | 11.44% | 4.00% | 11.29% | 1.42% | 5.01% | 84.38% | 17.22% | 9.77% | 14.58% | 14.05% | 13.94% | 10.95% | 20.02% | 29.01% | 28.08% | 18.33% | 16.90% |
| EPS | $0.35 | $0.78 | $0.77 | $0.64 | $0.21 | $0.83 | $0.08 | $0.28 | $0.01 | $0.59 | $0.55 | $1.42 | $1.40 | $1.42 | $1.12 | $2.20 | $3.39 | $3.40 | $1.58 | $1.23 |
| EPS Diluted | $0.35 | $0.78 | $0.77 | $0.64 | $0.23 | $0.83 | $0.08 | $0.28 | $0.20 | $0.77 | $0.55 | $1.42 | $1.40 | $1.41 | $1.11 | $2.19 | $3.37 | $3.38 | $1.57 | $1.23 |
| Weighted Average Shares Outstanding | 120.23M | 130.20M | 122.81M | 123.35M | 123.43M | 123.43M | 123.99M | 125.22M | 2.89B | 165.60M | 126.38M | 126.13M | 126.14M | 126.24M | 114.51M | 111.97M | 112.03M | 112.09M | 111.68M | 111.33M |
| Weighted Average Shares Outstanding Diluted | 120.23M | 121.58M | 123.03M | 123.48M | 123.54M | 123.43M | 124.20M | 125.40M | 126.47M | 126.48M | 126.54M | 126.51M | 126.64M | 126.72M | 115.02M | 112.42M | 112.50M | 112.54M | 112.29M | 111.87M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 29, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.16B | $913.16M | $454.36M | $618.32M | $402.04M |
| Short Term Investments | $- | $689.92M | $- | $- | $- |
| Cash and Short Term Investments | $1.16B | $1.60B | $454.36M | $618.32M | $402.04M |
| Net Receivables | $632.40M | $632.81M | $612.78M | $707.94M | $1.16B |
| Inventory | $367.59M | $428.06M | $405.46M | $624.71M | $514.57M |
| Other Current Assets | $186.22M | $337.14M | $1.82B | $703.63M | $167.21M |
| Total Current Assets | $2.35B | $3.00B | $3.30B | $2.44B | $2.29B |
| Property Plant Equipment Net | $649.93M | $664.74M | $671.30M | $753.38M | $575.54M |
| Goodwill | $6.46B | $6.53B | $6.48B | $7.42B | $3.45B |
| Intangible Assets | $2.64B | $3.02B | $3.38B | $4.06B | $1.37B |
| Goodwill and Intangible Assets | $9.10B | $9.56B | $9.86B | $11.48B | $4.81B |
| Long Term Investments | $- | $82.80M | $144.62M | $110.94M | $24.66M |
| Tax Assets | $- | $8.16M | $18.53M | $18.53M | $65.52M |
| Other Non-Current Assets | $288.40M | $252.01M | $135.64M | $212.23M | $242.87M |
| Total Non-Current Assets | $10.04B | $10.56B | $10.83B | $12.57B | $5.72B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $12.39B | $13.56B | $14.13B | $15.02B | $8.01B |
| Account Payables | $167.46M | $204.12M | $272.83M | $324.81M | $327.32M |
| Short Term Debt | $242.00K | $754.78M | $502.15M | $33.55M | $421.28M |
| Tax Payables | $- | $88.16M | $45.62M | $90.96M | $97.41M |
| Deferred Revenue | $- | $135.56M | $135.53M | $303.51M | $393.64M |
| Other Current Liabilities | $485.39M | $267.85M | $588.36M | $764.42M | $412.54M |
| Total Current Liabilities | $653.10M | $1.45B | $1.57B | $1.23B | $1.70B |
| Long Term Debt | $3.30B | $3.31B | $4.09B | $5.13B | $1.80B |
| Deferred Revenue Non-Current | $- | $- | $-4.32B | $-5.98B | $-774.53M |
| Deferred Tax Liabilities Non-Current | $- | $- | $1.11B | $1.48B | $774.53M |
| Other Non-Current Liabilities | $770.52M | $930.95M | $1.11B | $1.52B | $774.53M |
| Total Non-Current Liabilities | $4.07B | $4.24B | $5.17B | $6.65B | $2.57B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $4.73B | $5.69B | $6.73B | $7.89B | $4.27B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $7.67B | $123.43M | $126.30M | $126.24M | $112.09M |
| Retained Earnings | $- | $5.61B | $4.95B | $4.42B | $3.51B |
| Accumulated Other Comprehensive Income Loss | $- | $-276.69M | $-447.50M | $-162.69M | $-31.96M |
| Other Total Stockholders Equity | $- | $2.42B | $2.75B | $2.76B | $148.10M |
| Total Stockholders Equity | $7.67B | $7.87B | $7.39B | $7.13B | $3.74B |
| Total Equity | $7.67B | $7.87B | $7.39B | $7.13B | $3.74B |
| Total Liabilities and Stockholders Equity | $12.39B | $13.56B | $14.13B | $15.02B | $8.01B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $12.39B | $13.56B | $14.13B | $15.02B | $8.01B |
| Total Investments | $- | $689.92M | $144.62M | $110.94M | $24.66M |
| Total Debt | $3.30B | $4.07B | $4.56B | $5.17B | $2.18B |
| Net Debt | $2.14B | $3.15B | $4.11B | $4.55B | $1.78B |
Balance Sheet Charts
| Breakdown | March 30, 2025 | December 29, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | April 02, 2023 | January 01, 2023 | October 02, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.14B | $1.16B | $1.23B | $1.25B | $999.47M | $914.37M | $1.14B | $1.33B | $2.27B | $454.36M | $400.74M | $361.93M | $669.75M | $618.32M | $487.37M | $572.81M | $988.23M | $402.04M | $258.29M | $218.54M |
| Short Term Investments | $- | $- | $- | $706.07M | $697.33M | $689.92M | $292.97M | $739.05M | $193.96M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.14B | $1.16B | $1.23B | $1.95B | $1.70B | $1.60B | $1.43B | $2.07B | $2.46B | $454.36M | $400.74M | $361.93M | $669.75M | $618.32M | $487.37M | $572.81M | $988.23M | $402.04M | $258.29M | $218.54M |
| Net Receivables | $617.42M | $632.40M | $602.14M | $597.44M | $588.97M | $632.81M | $644.57M | $626.93M | $586.92M | $612.78M | $540.87M | $932.13M | $941.72M | $707.94M | $947.80M | $992.60M | $978.60M | $1.16B | $797.91M | $708.80M |
| Inventory | $381.31M | $367.59M | $404.57M | $401.43M | $414.03M | $428.06M | $435.70M | $436.82M | $429.42M | $405.46M | $378.26M | $624.30M | $645.92M | $624.71M | $645.42M | $513.43M | $529.91M | $514.57M | $486.56M | $477.71M |
| Other Current Assets | $181.59M | $186.22M | $211.92M | $205.63M | $360.93M | $337.14M | $403.27M | $388.63M | $318.12M | $1.82B | $1.80B | $190.48M | $197.11M | $703.63M | $170.21M | $181.15M | $177.83M | $167.21M | $133.06M | $126.37M |
| Total Current Assets | $2.32B | $2.35B | $2.45B | $3.16B | $3.06B | $3.00B | $2.91B | $3.52B | $3.80B | $3.29B | $3.12B | $2.11B | $2.45B | $2.44B | $2.25B | $2.26B | $2.67B | $2.29B | $1.68B | $1.53B |
| Property Plant Equipment Net | $660.38M | $649.93M | $667.24M | $646.91M | $652.69M | $664.74M | $645.89M | $657.99M | $659.07M | $671.30M | $620.52M | $742.98M | $749.00M | $753.38M | $746.37M | $587.56M | $584.41M | $575.54M | $530.34M | $518.01M |
| Goodwill | $6.51B | $6.46B | $6.56B | $6.50B | $6.50B | $6.53B | $6.47B | $6.52B | $6.51B | $6.48B | $6.37B | $7.24B | $7.37B | $7.42B | $7.42B | $3.84B | $3.68B | $3.45B | $3.16B | $3.11B |
| Intangible Assets | $2.57B | $2.64B | $2.76B | $2.83B | $2.92B | $3.02B | $3.09B | $3.20B | $3.29B | $3.38B | $3.40B | $3.77B | $3.94B | $4.06B | $4.16B | $1.56B | $1.47B | $1.37B | $1.18B | $1.19B |
| Goodwill and Intangible Assets | $9.08B | $9.10B | $9.32B | $9.32B | $9.42B | $9.56B | $9.56B | $9.72B | $9.80B | $9.86B | $9.77B | $11.01B | $11.31B | $11.48B | $11.58B | $5.41B | $5.16B | $4.81B | $4.34B | $4.30B |
| Long Term Investments | $- | $- | $- | $- | $- | $114.69M | $- | $- | $- | $107.19M | $- | $- | $- | $83.38M | $- | $152.14M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $8.16M | $- | $- | $- | $- | $- | $- | $- | $22.01M | $- | $-152.14M | $- | $- | $- | $- |
| Other Non-Current Assets | $299.55M | $288.40M | $332.22M | $296.79M | $297.63M | $220.12M | $307.03M | $321.57M | $382.87M | $203.87M | $312.30M | $324.25M | $334.79M | $236.32M | $321.67M | $334.16M | $346.70M | $333.05M | $315.65M | $291.56M |
| Total Non-Current Assets | $10.04B | $10.04B | $10.32B | $10.27B | $10.37B | $10.56B | $10.51B | $10.70B | $10.84B | $10.84B | $10.71B | $12.08B | $12.39B | $12.57B | $12.65B | $6.48B | $6.09B | $5.72B | $5.19B | $5.11B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $12.36B | $12.39B | $12.77B | $13.42B | $13.43B | $13.56B | $13.42B | $14.22B | $14.64B | $14.13B | $13.82B | $14.19B | $14.85B | $15.02B | $14.90B | $8.74B | $8.76B | $8.01B | $6.87B | $6.63B |
| Account Payables | $178.09M | $167.46M | $176.41M | $174.87M | $183.53M | $204.12M | $188.30M | $235.72M | $266.88M | $272.83M | $275.82M | $333.71M | $376.69M | $324.81M | $320.44M | $324.71M | $339.33M | $327.32M | $258.04M | $255.14M |
| Short Term Debt | $242.00K | $242.00K | $1.04M | $711.41M | $711.44M | $754.78M | $727.54M | $478.94M | $479.42M | $502.15M | $503.55M | $4.18M | $3.73M | $33.55M | $4.49M | $4.67M | $358.44M | $421.28M | $360.22M | $346.34M |
| Tax Payables | $- | $- | $- | $- | $- | $88.16M | $- | $- | $- | $- | $- | $- | $- | $90.96M | $- | $- | $- | $97.41M | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $135.56M | $- | $- | $- | $- | $- | $1 | $- | $303.51M | $- | $- | $- | $393.64M | $- | $- |
| Other Current Liabilities | $469.86M | $485.39M | $510.49M | $503.73M | $479.25M | $267.85M | $532.00M | $652.17M | $817.43M | $769.51M | $706.36M | $705.92M | $882.63M | $764.42M | $820.11M | $793.44M | $822.75M | $412.54M | $626.54M | $561.78M |
| Total Current Liabilities | $648.19M | $653.10M | $687.94M | $1.39B | $1.37B | $1.45B | $1.45B | $1.37B | $1.56B | $1.54B | $1.49B | $1.04B | $1.26B | $1.23B | $1.15B | $1.12B | $1.52B | $1.70B | $1.24B | $826.68M |
| Long Term Debt | $3.33B | $3.30B | $3.31B | $3.29B | $3.29B | $3.31B | $3.29B | $4.03B | $4.03B | $4.09B | $4.04B | $4.67B | $5.04B | $5.17B | $5.28B | $2.54B | $2.41B | $1.80B | $1.67B | $1.80B |
| Deferred Revenue Non-Current | $- | $- | $- | $-755.65M | $-792.60M | $- | $- | $-953.84M | $- | $- | $- | $-1.13B | $-6.02B | $-5.98B | $- | $- | $- | $-774.53M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $878.79M | $919.79M | $- | $- | $953.84M | $- | $- | $- | $1.31B | $1.35B | $1.48B | $- | $- | $- | $774.53M | $- | $- |
| Other Non-Current Liabilities | $750.28M | $770.52M | $846.00M | $878.79M | $919.79M | $930.95M | $993.05M | $953.84M | $1.01B | $1.11B | $1.23B | $- | $1.35B | $1.48B | $1.51B | $838.97M | $827.64M | $- | $720.80M | $703.21M |
| Total Non-Current Liabilities | $4.08B | $4.07B | $4.16B | $4.16B | $4.21B | $4.24B | $4.28B | $4.98B | $5.04B | $5.20B | $5.27B | $5.98B | $6.40B | $6.65B | $6.80B | $3.38B | $3.24B | $2.57B | $2.39B | $2.84B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $4.72B | $4.73B | $4.85B | $5.55B | $5.59B | $5.69B | $5.73B | $6.35B | $6.60B | $6.75B | $6.76B | $7.02B | $7.66B | $7.89B | $7.94B | $4.50B | $4.76B | $4.27B | $3.63B | $3.67B |
| Preferred Stock | $- | $- | $- | $- | $7.72B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $120.65M | $122.09M | $123.37M | $123.49M | $123.43M | $123.35M | $124.35M | $125.98M | $126.30M | $126.22M | $126.22M | $126.14M | $126.24M | $126.20M | $112.03M | $112.07M | $112.09M | $111.88M | $111.50M |
| Retained Earnings | $- | $- | $5.76B | $5.67B | $5.63B | $5.61B | $5.54B | $5.54B | $5.51B | $4.95B | $4.83B | $4.76B | $4.59B | $4.42B | $4.24B | $4.12B | $3.88B | $3.51B | $3.13B | $2.97B |
| Accumulated Other Comprehensive Income Loss | $- | $- | $-231.91M | $-341.93M | $-325.35M | $-276.69M | $-379.24M | $-304.97M | $-304.38M | $-447.50M | $-649.78M | $-459.08M | $-246.72M | $-162.69M | $-146.20M | $-92.44M | $-104.17M | $-31.96M | $-143.77M | $-216.67M |
| Other Total Stockholders Equity | $7.64B | $7.55B | $2.27B | $2.42B | $2.42B | $2.42B | $2.41B | $2.51B | $2.70B | $2.75B | $2.75B | $2.74B | $2.72B | $2.76B | $2.74B | $103.39M | $115.69M | $148.10M | $128.82M | $106.74M |
| Total Stockholders Equity | $7.64B | $7.67B | $7.92B | $7.87B | $7.85B | $7.87B | $7.69B | $7.87B | $8.03B | $7.38B | $7.07B | $7.17B | $7.19B | $7.13B | $6.96B | $4.24B | $4.00B | $3.74B | $3.23B | $2.96B |
| Total Equity | $7.64B | $7.67B | $7.92B | $7.87B | $7.85B | $7.87B | $7.69B | $7.87B | $8.03B | $7.38B | $7.07B | $7.17B | $7.19B | $7.13B | $6.96B | $4.24B | $4.00B | $3.74B | $3.23B | $2.96B |
| Total Liabilities and Stockholders Equity | $12.36B | $12.39B | $12.77B | $13.42B | $13.43B | $13.56B | $13.42B | $14.22B | $14.64B | $14.13B | $13.82B | $14.19B | $14.85B | $15.02B | $14.90B | $8.74B | $8.76B | $8.01B | $6.87B | $6.63B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $12.36B | $12.39B | $12.77B | $13.42B | $13.43B | $13.56B | $13.42B | $14.22B | $14.64B | $14.13B | $13.82B | $14.19B | $14.85B | $15.02B | $14.90B | $8.74B | $8.76B | $8.01B | $6.87B | $6.63B |
| Total Investments | $- | $- | $1.03M | $706.07M | $697.33M | $689.92M | $292.97M | $739.05M | $193.96M | $107.19M | $- | $- | $- | $83.38M | $- | $152.14M | $- | $- | $- | $- |
| Total Debt | $3.33B | $3.30B | $3.32B | $4.00B | $4.00B | $4.03B | $4.01B | $4.51B | $4.51B | $4.60B | $4.54B | $4.67B | $5.05B | $5.17B | $5.29B | $2.54B | $2.77B | $2.18B | $2.03B | $2.15B |
| Net Debt | $2.19B | $2.14B | $2.09B | $2.75B | $3.00B | $3.12B | $2.88B | $3.17B | $2.24B | $4.14B | $4.14B | $4.31B | $4.38B | $4.55B | $4.80B | $1.97B | $1.78B | $1.78B | $1.77B | $1.93B |
Annual Cash Flow
| Breakdown | December 29, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $270.38M | $179.50M | $579.18M | $932.16M | $727.89M |
| Depreciation and Amortization | $427.85M | $431.77M | $427.00M | $358.00M | $246.51M |
| Deferred Income Tax | $-102.23M | $-97.48M | $-107.41M | $-36.42M | $-27.92M |
| Stock Based Compensation | $37.81M | $41.41M | $51.52M | $29.68M | $26.90M |
| Change in Working Capital | $- | $-391.35M | $-382.11M | $104.36M | $-115.80M |
| Accounts Receivables | $-15.97M | $-9.00M | $66.09M | $155.39M | $-423.87M |
| Inventory | $45.09M | $-14.11M | $-48.63M | $2.38M | $-122.51M |
| Accounts Payables | $-26.02M | $-76.43M | $-43.80M | $823.00K | $62.75M |
| Other Working Capital | $- | $-291.81M | $-355.76M | $-54.23M | $367.82M |
| Other Non Cash Items | $-5.51M | $-72.58M | $111.63M | $19.86M | $32.38M |
| Net Cash Provided by Operating Activities | $628.30M | $91.27M | $679.81M | $1.41B | $892.18M |
| Investments in Property Plant and Equipment | $-86.65M | $-81.37M | $-85.63M | $-99.89M | $-77.51M |
| Acquisitions Net | $- | $-2.09M | $6.99M | $-3.99B | $-407.21M |
| Purchases of Investments | $-6.59M | $-1.23B | $-47.18M | $-23.13M | $-20.06M |
| Sales Maturities of Investments | $- | $550.00M | $85.63M | $99.89M | $77.51M |
| Other Investing Activities | $869.40M | $2.07B | $-92.66M | $-99.78M | $-77.22M |
| Net Cash Used for Investing Activities | $776.16M | $1.31B | $-132.85M | $-4.11B | $-504.50M |
| Debt Repayment | $-723.07M | $-517.49M | $-559.17M | $3.07B | $-187.47M |
| Common Stock Issued | $- | $- | $14.11M | $25.12M | $37.67M |
| Common Stock Repurchased | $-369.58M | $-388.88M | $-80.64M | $-73.07M | $-6.94M |
| Dividends Paid | $-34.45M | $-34.97M | $-35.34M | $-32.37M | $-31.21M |
| Other Financing Activities | $-1.13M | $-5.79M | $13.35M | $-26.87M | $-14.92M |
| Net Cash Used Provided by Financing Activities | $-1.13B | $-947.12M | $-661.80M | $2.94B | $-202.87M |
| Effect of Forex Changes on Cash | $-26.15M | $-14.05M | $-33.75M | $-22.93M | $25.91M |
| Net Change in Cash | $250.08M | $443.63M | $-148.59M | $216.72M | $210.72M |
| Cash at End of Period | $1.16B | $914.37M | $470.75M | $619.34M | $402.61M |
| Cash at Beginning of Period | $914.37M | $470.75M | $619.34M | $402.61M | $191.89M |
| Operating Cash Flow | $628.30M | $91.27M | $679.81M | $1.41B | $892.18M |
| Capital Expenditure | $-86.65M | $-81.37M | $-85.63M | $-99.89M | $-77.51M |
| Free Cash Flow | $541.65M | $9.90M | $594.18M | $1.31B | $814.67M |
Cash Flow Charts
| Breakdown | March 30, 2025 | December 29, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | April 02, 2023 | January 01, 2023 | October 02, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $42.24M | $94.64M | $93.39M | $72.61M | $28.70M | $63.57M | $32.47M | $58.62M | $569.48M | $127.66M | $85.35M | $179.25M | $176.96M | $179.18M | $127.74M | $245.93M | $379.31M | $380.36M | $176.74M | $137.21M |
| Depreciation and Amortization | $97.42M | $106.06M | $107.67M | $107.24M | $107.80M | $105.57M | $108.26M | $108.93M | $110.80M | $105.50M | $104.74M | $119.41M | $120.05M | $125.07M | $87.11M | $75.64M | $70.19M | $63.99M | $62.47M | $59.29M |
| Deferred Income Tax | $- | $- | $- | $- | $- | $-123.66M | $-50.73M | $-88.56M | $- | $- | $- | $- | $- | $-36.42M | $- | $- | $- | $-27.92M | $- | $- |
| Stock Based Compensation | $7.73M | $5.05M | $10.54M | $10.53M | $11.69M | $7.18M | $10.70M | $13.63M | $9.89M | $11.74M | $2.80M | $15.23M | $15.26M | $13.82M | $6.60M | $7.20M | $5.16M | $9.36M | $7.12M | $9.60M |
| Change in Working Capital | $- | $61.85M | $-48.49M | $-11.69M | $-18.74M | $82.79M | $-147.63M | $-234.42M | $-90.69M | $65.26M | $-62.76M | $-246.19M | $-74.07M | $60.05M | $56.83M | $-40.76M | $28.25M | $31.54M | $-43.18M | $-71.36M |
| Accounts Receivables | $18.14M | $-49.26M | $5.10M | $-8.99M | $37.19M | $21.92M | $-20.70M | $-44.64M | $34.42M | $-54.05M | $39.80M | $-21.58M | $69.06M | $-87.00M | $87.11M | $-9.92M | $165.19M | $-356.17M | $-72.01M | $-76.29M |
| Inventory | $-5.49M | $18.27M | $9.57M | $10.04M | $7.21M | $20.73M | $-8.06M | $-8.26M | $-18.52M | $-4.16M | $-12.68M | $-23.33M | $-46.97M | $-3.94M | $-923.00K | $22.25M | $-15.01M | $-1.58M | $5.77M | $-71.95M |
| Accounts Payables | $8.85M | $- | $-1.81M | $-4.75M | $-18.23M | $8.97M | $-36.17M | $-44.33M | $- | $- | $- | $-33.73M | $26.35M | $37.83M | $-10.21M | $-21.75M | $-5.05M | $46.36M | $-4.52M | $17.74M |
| Other Working Capital | $- | $92.84M | $-61.34M | $-7.99M | $-44.91M | $31.18M | $-82.71M | $-137.19M | $-106.59M | $123.47M | $-89.88M | $-167.54M | $-122.52M | $113.16M | $-19.16M | $-31.34M | $-116.88M | $342.93M | $27.57M | $59.13M |
| Other Non Cash Items | $-13.29M | $-93.37M | $-15.22M | $208.64M | $219.24M | $61.17M | $13.45M | $6.48M | $-536.02M | $-171.00M | $29.83M | $362.47M | $45.01M | $-6.12M | $35.52M | $-145.00K | $-9.40M | $24.77M | $8.29M | $3.85M |
| Net Cash Provided by Operating Activities | $134.10M | $174.23M | $147.88M | $158.62M | $147.56M | $196.61M | $-33.48M | $-135.32M | $63.46M | $139.16M | $159.95M | $97.48M | $283.21M | $335.59M | $313.80M | $287.86M | $473.50M | $482.10M | $211.43M | $138.60M |
| Investments in Property Plant and Equipment | $-15.98M | $-24.45M | $-22.32M | $-22.03M | $-17.84M | $-24.12M | $-22.36M | $-13.95M | $-20.95M | $-26.13M | $-13.03M | $-23.15M | $-29.43M | $-32.43M | $-32.78M | $-20.36M | $-14.31M | $-20.11M | $-20.25M | $-16.65M |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $-1.25M | $13.95M | $-686.00K | $250.00K | $-2.13M | $-951.00K | $-3.88M | $-23.63M | $-3.26B | $-259.15M | $-443.54M | $-405.94M | $-104.00K | $-1.24M |
| Purchases of Investments | $- | $- | $- | $-4.34M | $-337.00K | $-390.69M | $-1.00M | $-642.76M | $- | $- | $- | $-4.25M | $-23.00M | $-4.00M | $-4.62M | $-10.51M | $-4.00M | $-10.50M | $-2.17M | $-5.75M |
| Sales Maturities of Investments | $- | $- | $712.50M | $- | $- | $-550.00M | $450.00M | $100.00M | $- | $- | $- | $- | $29.43M | $32.43M | $32.78M | $20.36M | $14.31M | $20.11M | $20.25M | $16.65M |
| Other Investing Activities | $9.60M | $7.12M | $- | $147.86M | $-337.00K | $550.00M | $9.47M | $-28.28M | $1.89B | $196.00K | $-7.34M | $-6.85M | $-29.43M | $109.00K | $-11.56M | $-10.51M | $-4.00M | $151.00K | $-1.56M | $79.00K |
| Net Cash Used for Investing Activities | $-6.38M | $-17.33M | $690.18M | $121.49M | $-18.18M | $-414.81M | $434.87M | $-571.04M | $1.86B | $-25.68M | $-22.51M | $-28.36M | $-56.31M | $-59.95M | $-3.30B | $-290.02M | $-461.85M | $-436.40M | $-22.52M | $-23.56M |
| Debt Repayment | $- | $-822.00K | $-711.05M | $- | $-10.81M | $- | $-467.14M | $-1.23M | $-41.74M | $-291.21M | $-57.13M | $-349.76M | $-101.06M | $-112.95M | $2.77B | $-216.99M | $630.51M | $78.86M | $-158.30M | $-87.75M |
| Common Stock Issued | $2.63M | $- | $141.00K | $- | $3.94M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-153.59M | $-185.16M | $-154.11M | $-19.55M | $-10.76M | $-4.87M | $-110.72M | $-211.64M | $-61.66M | $-24.50M | $-89.00K | $-456.00K | $-55.59M | $-59.00K | $-89.00K | $-30.14M | $-42.78M | $-115.00K | $-160.00K | $-327.00K |
| Dividends Paid | $-8.43M | $-8.54M | $-8.63M | $-8.64M | $-8.64M | $-8.64M | $-8.69M | $-8.80M | $-8.84M | $-8.84M | $-8.84M | $-8.83M | $-8.84M | $-8.83M | $-7.84M | $-7.84M | $-7.85M | $-7.83M | $-7.81M | $-7.79M |
| Other Financing Activities | $- | $1.53M | $-83.00K | $1.70M | $-4.81M | $-6.11M | $493.00K | $-6.60M | $-952.00K | $247.86M | $413.00K | $4.44M | $635.00K | $-17.18M | $-9.69M | $-2.74M | $3.11M | $2.52M | $10.33M | $97.00K |
| Net Cash Used Provided by Financing Activities | $- | $-192.99M | $-873.74M | $-26.50M | $-35.01M | $-19.61M | $-586.05M | $-228.27M | $-113.19M | $-76.70M | $-65.64M | $-354.61M | $-164.86M | $-139.03M | $2.76B | $-257.72M | $582.99M | $73.43M | $-155.94M | $-95.77M |
| Effect of Forex Changes on Cash | $16.12M | $-30.27M | $17.05M | $-3.65M | $-9.28M | $14.22M | $-10.70M | $-602.00K | $-16.97M | $17.66M | $-17.43M | $-23.34M | $-10.64M | $-6.34M | $-5.92M | $-3.81M | $-6.85M | $25.08M | $5.49M | $5.51M |
| Net Change in Cash | $- | $-66.36M | $-18.62M | $250.04M | $85.09M | $-222.35M | $-195.36M | $-935.24M | $1.80B | $54.43M | $54.38M | $-308.82M | $51.41M | $130.28M | $-237.64M | $-263.70M | $587.79M | $144.21M | $38.46M | $24.77M |
| Cash at End of Period | $- | $1.16B | $1.23B | $1.25B | $999.47M | $914.37M | $1.14B | $1.33B | $2.27B | $470.75M | $416.31M | $361.93M | $670.75M | $619.34M | $489.06M | $726.70M | $990.40M | $402.61M | $258.40M | $219.94M |
| Cash at Beginning of Period | $- | $1.23B | $1.25B | $998.08M | $914.37M | $1.14B | $1.33B | $2.27B | $470.75M | $416.31M | $361.93M | $670.75M | $619.34M | $489.06M | $726.70M | $990.40M | $402.61M | $258.40M | $219.94M | $195.17M |
| Operating Cash Flow | $134.10M | $174.23M | $147.88M | $158.62M | $147.56M | $196.61M | $-33.48M | $-135.32M | $63.46M | $139.16M | $159.95M | $97.48M | $283.21M | $335.59M | $313.80M | $287.86M | $473.50M | $482.10M | $211.43M | $138.60M |
| Capital Expenditure | $-15.98M | $-24.45M | $-22.32M | $-22.03M | $-17.84M | $-24.12M | $-22.36M | $-13.95M | $-20.95M | $-26.13M | $-13.03M | $-23.15M | $-29.43M | $-32.43M | $-32.78M | $-20.36M | $-14.31M | $-20.11M | $-20.25M | $-16.65M |
| Free Cash Flow | $118.11M | $149.78M | $125.57M | $136.59M | $129.72M | $172.50M | $-55.84M | $-149.27M | $42.52M | $113.03M | $146.92M | $74.33M | $253.78M | $303.16M | $281.01M | $267.50M | $459.19M | $461.98M | $191.18M | $121.95M |
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
$92.66
Stock Price
$11.13B
Market Cap
11.00K
Employees
Waltham, MA
Location
Revenue (FY 2024)
$2.76B
0.2% YoY
Net Income (FY 2024)
$270.38M
-61.0% YoY
EPS (FY 2024)
$2.20
-60.4% YoY
Free Cash Flow (FY 2024)
$541.65M
5369.0% YoY
Profitability
Gross Margin
55.8%
Net Margin
9.8%
ROE
3.5%
ROA
2.2%
Valuation
P/E Ratio
48.40
P/S Ratio
4.75
EV/EBITDA
17.95
Market Cap
$11.13B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$628.30M
588.4% YoY
Free Cash Flow
$541.65M
5369.0% YoY
Balance Sheet Summary
Total Assets
$12.39B
-8.6% YoY
Total Debt
$3.30B
18.8% YoY
Shareholder Equity
$7.67B
3.3% YoY
Dividend Overview
$0.07
Latest Dividend
%
Dividend Yield
%
Payout Ratio
Recent Dividend History
| Date | Amount | Type |
|---|---|---|
| 2025-07-18 | $0.07 | July 18, 25 |
| 2025-04-17 | $0.07 | April 17, 25 |
| 2025-01-17 | $0.07 | January 17, 25 |
| 2024-10-18 | $0.07 | October 18, 24 |
| 2024-07-19 | $0.07 | July 19, 24 |
| 2024-04-18 | $0.07 | April 18, 24 |
| 2024-01-18 | $0.07 | January 18, 24 |
| 2023-10-19 | $0.07 | October 19, 23 |
| 2023-07-20 | $0.07 | July 20, 23 |
| 2023-04-20 | $0.07 | April 20, 23 |
Revvity Dividends
Explore Revvity's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
0.26%
Dividend Payout Ratio
12.74%
Dividend Paid & Capex Coverage Ratio
5.19x
Revvity Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.07 | $0.07 | July 18, 2025 | July 18, 2025 | August 08, 2025 | April 24, 2025 |
| $0.07 | $0.07 | April 17, 2025 | April 18, 2025 | May 09, 2025 | January 23, 2025 |
| $0.07 | $0.07 | January 17, 2025 | January 17, 2025 | February 07, 2025 | October 24, 2024 |
| $0.07 | $0.07 | October 18, 2024 | October 18, 2024 | November 08, 2024 | July 25, 2024 |
| $0.07 | $0.07 | July 19, 2024 | July 19, 2024 | August 09, 2024 | April 25, 2024 |
| $0.07 | $0.07 | April 18, 2024 | April 19, 2024 | May 10, 2024 | January 25, 2024 |
| $0.07 | $0.07 | January 18, 2024 | January 19, 2024 | February 09, 2024 | October 26, 2023 |
| $0.07 | $0.07 | October 19, 2023 | October 20, 2023 | November 10, 2023 | July 21, 2023 |
| $0.07 | $0.07 | July 20, 2023 | July 21, 2023 | August 11, 2023 | April 25, 2023 |
| $0.07 | $0.07 | April 20, 2023 | April 21, 2023 | May 12, 2023 | |
| $0.07 | $0.07 | January 19, 2023 | January 20, 2023 | February 10, 2023 | |
| $0.07 | $0.07 | October 20, 2022 | October 21, 2022 | November 11, 2022 | |
| $0.07 | $0.07 | July 21, 2022 | July 22, 2022 | August 12, 2022 | |
| $0.07 | $0.07 | April 21, 2022 | April 22, 2022 | May 13, 2022 | |
| $0.07 | $0.07 | January 20, 2022 | January 21, 2022 | February 11, 2022 | |
| $0.07 | $0.07 | October 21, 2021 | October 22, 2021 | November 12, 2021 | |
| $0.07 | $0.07 | July 15, 2021 | July 16, 2021 | August 06, 2021 | |
| $0.07 | $0.07 | April 15, 2021 | April 16, 2021 | May 07, 2021 | |
| $0.07 | $0.07 | January 21, 2021 | January 22, 2021 | February 12, 2021 | |
| $0.07 | $0.07 | October 15, 2020 | October 16, 2020 | November 06, 2020 |
Revvity News
Read the latest news about Revvity, including recent articles, headlines, and updates.
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and I will be coordinating your call today.
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity Announces Financial Results for the First Quarter of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operati.
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery.
Revvity to Hold Earnings Call on Monday, April 28, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of t.
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster hig.
Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle. The Signals One platform addresses the growing complexity of drug modalities research by delivering a complete solution that integrates advanced research capabilities a.
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software. This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted access to Spotfire software and support for Revvity and its customers, protecting operat.
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor Conference Monday, March 3, 2025 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 45th Annual Health Care Conference Tuesday, March 4, 2025 9:10 a.m. ET - Prahlad Singh, president and chief executive officer Leerink Partners Global Healthcare Conference Tuesday, M.
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Patrick Donnelly - Citi Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Luke Sergott - Barclays Andrew Cooper - Raymond James Catherine Schulte - Baird Dan Brennan - TD Cowen Operator Hello, everyone, and welcome to Revvity's Fourth Quarter 2024 Earnings Call. My name is Lydia, and I will be your operator today.
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP earnings per share of $0.78, as compared to $0.64 in the same period a year ago. GAAP revenue for the quarter was $729 million, as compared to $696 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $119 million, as compared to $77 million f.
Revvity Ignites Scientific Breakthroughs at SLAS2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity's Harmony™ and Signals Image Artist™ software packages, the Phenologic.AI software leverages pre-trained deep-learning models to analyze brightfield images, providing an additional multiplexing channel and streamlined workflows for live cell analysis. This significant advancement expand.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for RVTY.